BRAIN Biotech AG (HAM:BNN) Mohanram G-Score: 2 (As of Mar. 2026) — 100% Above Median


HAM:BNN BRAIN Biotech AG HAM:BNN
65 GF Score
Price €2.72
GF Value €2.56
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BRAIN Biotech AG Mohanram G-Score?

BRAIN Biotech AG HAM:BNN -3.89% 65 Mohanram G-Score is 2 as of Mar. 2026, which is 100% above its 10-year median of 1.00. GuruFocus rates HAM:BNN with a GF Score™ of 65/100 and a GF Value™ of €2.56 (Fairly Valued). The stock has 2 warning signs investors should review.

Mohanram G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. Companies have higher G-score tends to generate higher return. According to his study, the best growth stocks that have a G-Score greater than 6 tend to beat the market, while those with a G-Score lower than 1 tend to have negative absolute returns.

Thus, the zones of discrimination were as such:

Good or high score = 6, 7, 8
Bad or low score = 0, 1

BRAIN Biotech AG has an G-score of 2.

The historical rank and industry rank for BRAIN Biotech AG's Mohanram G-Score or its related term are showing as below:

HAM:BNN' s Mohanram G-Score Range Over the Past 10 Years
Min: 0   Med: 1   Max: 2
Current: 2

During the past 11 years, the highest Piotroski G-score of BRAIN Biotech AG was 2. The lowest was 0. And the median was 1.

BRAIN Biotech AG  (HAM:BNN) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


BRAIN Biotech AG Mohanram G-Score Related Terms


BRAIN Biotech AG Mohanram G-Score Historical Data

* Premium members only.

The historical data trend for BRAIN Biotech AG's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRAIN Biotech AG Mohanram G-Score Chart

BRAIN Biotech AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Mohanram G-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 0.00 1.00 2.00 2.00

BRAIN Biotech AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 1.00 2.00 2.00 2.00

HAM:BNN vs LIN, SHW, ECL: Mohanram G-Score Comparison

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BRAIN Biotech AG Mohanram G-Score vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Mohanram G-Score falls into.


HAM:BNN
65GF Score
BRAIN Biotech AG HAM:BNN
Mohanram G-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BRAIN Biotech AG Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

BRAIN Biotech AG has an G-score of 2.

Frequently Asked Questions Learn more about Mohanram G-Score →
What does a Mohanram G-Score of 2 mean?
BRAIN Biotech AG (HAM:BNN) has a Mohanram G-Score of 2 as of Mar. 2026. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on BRAIN Biotech AG and its competitors. This is 100% above median its historical median of 1.00.
Is BRAIN Biotech AG's Mohanram G-Score too high?
BRAIN Biotech AG's current Mohanram G-Score of 2 is 100% above median its 10-year median of 1.00. Overall, BRAIN Biotech AG has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Mohanram G-Score compare to LIN and SHW?
BRAIN Biotech AG's Mohanram G-Score of 2 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Mohanram G-Score for a Chemicals company?
A good Mohanram G-Score depends on the Chemicals industry context. However, Mohanram G-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Mohanram G-Score mean?
A high Mohanram G-Score can signal that a stock is expensive relative to its fundamentals. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on BRAIN Biotech AG and its competitors. BRAIN Biotech AG's current Mohanram G-Score is 2, which is 100% above median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Fairly Valued. The stock's GF Value™ is €2.56, compared to a current price of €2.72 — trading 6.3% above its estimated fair value. The current Mohanram G-Score is 2, which is 100% above median its 10-year median of 1.00. BRAIN Biotech AG's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Mohanram G-Score calculated?
Mohanram G-Score is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Mohanram G-Score is 2 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.72 is trading 6.3% above its estimated GF Value™ of €2.56. GuruFocus considers BRAIN Biotech AG to be Fairly Valued.

Key valuation signals for HAM:BNN:

  • Mohanram G-Score: 2 (100% above median its 10-year median of 1.00)
  • GF Value™: €2.56 vs. price of €2.72 (6.3% above fair value)
  • GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BRAIN Biotech AG Business Description

Other Exchanges 0RFI:UKBNN:Germany
Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
65GF Score

Get the complete analysis for HAM:BNN

Mohanram G-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.72
Price
€2.56
GF Value